10-Q: Achieve Life Sciences Reports Q1 2024 Results, Advances Cytisinicline Development

Achieve Life Sciences reported a net loss of $6.5 million for Q1 2024, while also securing $56.1 million in net proceeds from a private placement to advance the development of cytisinicline.

Summary

• Achieve Life Sciences reported a net loss of $6.5 million for the first quarter of 2024, compared to a net loss of $8.99 million for the same period in 2023.
• The company's research and development expenses decreased to $2.8 million in Q1 2024 from $5.5 million in Q1 2023, primarily due to the completion of Phase 3 ORCA-3 and Phase 2 ORCA-V1 trials.
• General and administrative expenses increased slightly to $3.2 million in Q1 2024 from $3.0 million in Q1 2023.
• The company's cash and cash equivalents balance was $66.4 million as of March 31, 2024, with a positive working capital balance of $47.1 million.
• Net cash used in operating activities was $5.3 million for the three months ended March 31, 2024.
• Achieve Life Sciences secured $56.1 million in net proceeds from a February 2024 private placement.
• The company plans to initiate an open-label trial, ORCA-OL, in the second quarter of 2024 to evaluate the long-term safety of cytisinicline, with an NDA submission anticipated in the first half of 2025.
• The company has a convertible term loan of $16.6 million that may mature on August 1, 2024, if certain conditions related to the FDA's acceptance of the NDA are not met.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has made progress in clinical trials and secured significant funding, it continues to operate at a loss and faces several risks, including debt obligations and reliance on a single supplier. The positive clinical trial results and the agreement with the FDA are encouraging, but the financial challenges and competitive landscape temper the overall outlook.

Positives

• The company has a strong cash position of $66.4 million, providing a financial runway into the second half of 2025.
• The successful private placement in February 2024 significantly boosted the company's financial resources.
• The company has reached an agreement with the FDA on the design of the ORCA-OL trial, which is expected to support the NDA submission.
• The company has completed three additional Phase 1 clinical studies for the NDA, including renal impairment, PK, and cardiac safety studies.
• The company has completed Phase 2 ORCA-1 and ORCA-V1 trials, and Phase 3 ORCA-2 and ORCA-3 trials, all with positive results.

Negatives

• The company continues to incur net losses, with a $6.5 million loss reported for Q1 2024.
• The company is dependent on a single supplier, Sopharma, for the manufacture of cytisinicline.
• The company's convertible term loan of $16.6 million may mature on August 1, 2024, if certain conditions are not met, creating a potential near-term financial obligation.
• The company has no current sources of revenue and is dependent on raising additional capital.
• The company is subject to various risks related to the development and regulatory approval of cytisinicline.

Risks

• The company's ability to obtain additional financing when needed is uncertain, which could impact the development and commercialization of cytisinicline.
• The company has substantial debt, which could impair its flexibility and access to capital.
• The company is dependent on a single product candidate, cytisinicline, and its success is not guaranteed.
• The company relies on a single company for the manufacture and supply of cytisinicline, creating a supply chain risk.
• The company's NDA submission for cytisinicline may not be successful, and the FDA may require additional studies.
• The company's product candidate may cause undesirable side effects, which could delay or prevent regulatory approval.
• The company faces substantial competition, and competitors may develop products faster or more successfully.
• The company may not be successful in obtaining or maintaining necessary rights to cytisinicline.
• The company's business may be negatively affected by weather conditions, natural disasters, and the availability of natural resources.
• The company's internal computer systems, or those of its third-party collaborators, may fail or suffer security breaches and cyber-attacks.

Future Outlook

The company anticipates an NDA submission for cytisinicline in the first half of 2025, following the completion of the ORCA-OL trial. The company believes its existing cash and cash equivalents will be sufficient to fund operations into the second half of 2025, including the potential NDA submission and repayment of debt obligations.

Management Comments

• The FDA expressed support for an NDA submission based on adequate data to assess for efficacy from our two completed randomized and controlled Phase 3 trials.
• The FDA advised that long-term exposure data to assess for safety beyond 12 weeks would be needed to adequately assess safety risks.
• We reached agreement with the FDA that a single, open-label study evaluating the long-term safety effects of cytisinicline will be sufficient to complete the requirement and enable an NDA submission anticipated in the first half of 2025.

Industry Context

The document highlights the significant unmet need for effective smoking cessation treatments, with an estimated 28 million adults in the United States who smoke combustible cigarettes and 11 million who use e-cigarettes. The company positions cytisinicline as a potential first-in-class treatment that could address this need, differentiating itself from existing treatments with its combination of efficacy, minimal side effects, and optional shorter course of therapy.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies' financial results, but it does highlight the competitive landscape in the smoking cessation market.
• The company's clinical trial results for cytisinicline are compared to placebo groups, demonstrating statistically significant improvements in quit rates.
• The document mentions that cytisinicline may become one of the first new prescription medicines in nearly two decades aimed at aiding individuals in overcoming nicotine dependence, suggesting a potential advantage over existing treatments.
• The company's approach to long-term safety data collection through the ORCA-OL trial is in line with FDA requirements for smoking cessation drugs, which are viewed as products for chronic, repeated, and intermittent use.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is crucial for its success.
• Customers: The potential approval of cytisinicline could provide a new treatment option for smokers and e-cigarette users.
• Suppliers: The company's reliance on Sopharma for cytisinicline supply creates a dependency risk.
• Creditors: The company's debt obligations and ability to repay them will impact its financial stability.

Next Steps

• Initiate the ORCA-OL trial in the second quarter of 2024.
• Submit an NDA for cytisinicline to the FDA in the first half of 2025.
• Continue to explore alternative options for the convertible term loan, including with other lenders.
• Continue to advance the development of cytisinicline for smoking cessation and nicotine addiction.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine addiction, clinical trials, FDA, NDA, ORCA-OL, pharmaceutical, biotechnology, drug development